Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Gil-Redondo, R; Conde, R; Bruzzone, C; Seco, ML; Bizkarguenaga, M; González-Valle, B; de, Diego, A; Laín, A; Habisch, H; Haudum, C; Verheyen, N; Obermayer-Pietsch, B; Margarita, S; Pelusi, S; Verde, I; Oliveira, N; Sousa, A; Zabala-Letona, A; Santos-Martin, A; Loizaga-Iriarte, A; Unda-Urzaiz, M; Kazenwadel, J; Berezhnoy, G; Geisler, T; Gawaz, M; Cannet, C; Schäfer, H; Diercks, T; Trautwein, C; Carracedo, A; Madl, T; Valenti, L; Spraul, M; Lu, SC; Embade, N; Mato, JM; Millet, O.
MetSCORE: a molecular metric to evaluate the risk of metabolic syndrome based on serum NMR metabolomics.
Cardiovasc Diabetol. 2024; 23(1): 272
Doi: 10.1186/s12933-024-02363-3
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Habisch Hansjörg
- Haudum Christoph
- Madl Tobias
- Obermayer-Pietsch Barbara
- Verheyen Nicolas Dominik
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Metabolic syndrome (MetS) is a cluster of medical conditions and risk factors correlating with insulin resistance that increase the risk of developing cardiometabolic health problems. The specific criteria for diagnosing MetS vary among different medical organizations but are typically based on the evaluation of abdominal obesity, high blood pressure, hyperglycemia, and dyslipidemia. A unique, quantitative and independent estimation of the risk of MetS based only on quantitative biomarkers is highly desirable for the comparison between patients and to study the individual progression of the disease in a quantitative manner. METHODS: We used NMR-based metabolomics on a large cohort of donors (n = 21,323; 37.5% female) to investigate the diagnostic value of serum or serum combined with urine to estimate the MetS risk. Specifically, we have determined 41 circulating metabolites and 112 lipoprotein classes and subclasses in serum samples and this information has been integrated with metabolic profiles extracted from urine samples. RESULTS: We have developed MetSCORE, a metabolic model of MetS that combines serum lipoprotein and metabolite information. MetSCORE discriminate patients with MetS (independently identified using the WHO criterium) from general population, with an AUROC of 0.94 (95% CI 0.920-0.952, p < 0.001). MetSCORE is also able to discriminate the intermediate phenotypes, identifying the early risk of MetS in a quantitative way and ranking individuals according to their risk of undergoing MetS (for general population) or according to the severity of the syndrome (for MetS patients). CONCLUSIONS: We believe that MetSCORE may be an insightful tool for early intervention and lifestyle modifications, potentially preventing the aggravation of metabolic syndrome.
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- Metabolic Syndrome - diagnosis, blood, epidemiology, urine
- Female - administration & dosage
- Metabolomics - administration & dosage
- Male - administration & dosage
- Biomarkers - blood, urine
- Middle Aged - administration & dosage
- Risk Assessment - administration & dosage
- Predictive Value of Tests - administration & dosage
- Adult - administration & dosage
- Magnetic Resonance Spectroscopy - administration & dosage
- Aged - administration & dosage
- Lipoproteins - blood
- Prognosis - administration & dosage
- Risk Factors - administration & dosage
- Cardiometabolic Risk Factors - administration & dosage
- Young Adult - administration & dosage
- Find related publications in this database (Keywords)
- Metabolic syndrome
- Lipoproteins
- Obesity
- Dyslipidemia
- Diabetes
- Hypertension
- NMR spectroscopy
- Precision medicine